Venous thromboembolism in children with cancer – A population-based cohort study  by Walker, Alex J. et al.
Thrombosis Research 133 (2014) 340–344
Contents lists available at ScienceDirect
Thrombosis Research
j ourna l homepage: www.e lsev ie r .com/ locate / th romresRegular ArticleVenous thromboembolism in children with cancer – A population-based
cohort study☆☆Alex J. Walker a,b,⁎, Matthew J. Grainge a,b, Tim R. Card a,b, Joe West a,b, Susanna Ranta c, Jonas F. Ludvigsson d,e
a Division of Epidemiology and Public Health, University of Nottingham, Nottingham City Hospital, NG5 1PB UK
b Nottingham Digestive Diseases Centre, NIHR Biomedical Research Unit
c Childhood Cancer Research Unit, Karolinska Institutet Stockholm Sweden
d Department of Medical Epidemiology and Biostatistics, Karolinska Institutet Sockholm Sweden
e Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro SwedenAbbreviations: CI, Conﬁdence Interval; CVC, Central
ratio; PE, Pulmonary embolism; VTE, Venous thromboem
☆☆ Details of ethics approval: This project was appro
Scientiﬁc Advisory Committee (Protocol no. 10–091).
⁎ Corresponding author at: Epidemiology & Public
Sciences Building Phase 2, City Hospital, Hucknall Road, N
E-mail address: alex.walker@nottingham.ac.uk (A.J. W
0049-3848 © 2014 The Authors. Published by Elsevier Ltd
http://dx.doi.org/10.1016/j.thromres.2013.12.021a b s t r a c ta r t i c l e i n f oArticle history:
Received 25 October 2013
Received in revised form 29 November 2013
Accepted 16 December 2013







Introduction: Cancer is a known risk factor for venous thromboembolism (VTE) in adults, but population-based
data in children are scarce.
Materials and methods:We conducted a cohort study utilising linkage of the Clinical Practice Research Database
(primary care), Hospital Episodes Statistics (secondary care), UK Cancer Registry data and Ofﬁce for National Sta-
tistics cause of death data. From these databases, we selected 498 children with cancer diagnosed between 1997
and 2006 and 20,810 controls without cancer.We calculated VTE incidence rates in childrenwith cancer vs. con-
trols, and hazard ratios (HRs) using Cox regression.
Results:We identiﬁed four VTE events in children with cancer compared with four events in the larger control
population corresponding to absolute risks of 1.52 and 0.06 per 1000 person-years respectively. The four children
with VTE and cancer were diagnosed with hematological, bone or non-speciﬁed cancer. Childhood cancer was
hence associated with a highly increased risk of VTE (HR adjusted for age and sex: 28.3; 95%CI = 7.0-114.5).
Conclusions: Children with cancer are at increased relative risk of VTE compared to those without cancer. Physi-
cians could consider thromboprophylaxis in children with cancer to reduce their excess risk of VTE however the
absolute risk is extremely small and the beneﬁt gained therefore would need to be balanced against the risk in-
voked of implementing such a strategy.
Novelty & Impact Statements:While there is a reasonable level of knowledge about the risk of VTE in adult pop-
ulations, it is not well knownwhether this risk is reﬂected in paediatric patients.We found a substantial increase
in risk of VTE in childrenwith cancer compared to a child populationwithout cancer.While this ﬁnding is impor-
tant, the absolute risk of VTE is still low and must be balanced with the risks of anticoagulation.© 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY license.Introduction
Cancer is a leading cause of death in children in the Western world.
In the last 30 years, the survival rate has however improved dramatical-
ly, and today the 5-year-survival of both leukemia and Non Hodgkins
Lymphoma in children exceeds 85% [1]. With increasing survival rates,
health care in these children focuses more on the prevention ofvenous catheters; HR, Hazard
bolism.
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Health, Room B121, Clinical
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alker).
.Open access under CC BY license.complications from cancer and cancer treatment. One such complica-
tion is venous thromboembolism (VTE) [2–7]. VTE, deﬁned as deep-
vein thrombosis or pulmonary embolism, is a leading cause of non-
cancer death in adult patients with cancer [8].
As the treatment strategies for critically ill children have improved,
the rate of VTE in children has increased both in the general population
[9], and among patients with cancer [10]. VTE is also associated with a
substantial excess mortality [9,10] and seems to inﬂuence cancer mor-
tality even when tumour stage and cancer regimen have been taken
into consideration [11]. In a recent US study [9], Boulet et al. reported
that venous catheter use, mechanical ventilation, malignancy, and hos-
pitalization for at leastﬁve dayswere all risk factors for VTE-related hos-
pital admissions. Despite the identiﬁcation of these risk factors, few
studies have quantiﬁed the absolute and relative risks of VTE in cancer
compared with general population controls. We recently showed that
adults with cancer are at a 4-5-fold increased risk of VTE compared to
the general population [12]. Guidelines for adults stipulate that
thromboprophylaxis is advised for high-risk inpatients including those
Table 1
Characteristics of study participants.
Cancer patients % (IQR) Controls % (IQR)
Total 498 20 810
Median age (years) 7 (3–13) 8 (3–12)
Sex Male 273 54.8 10 694 51.4
Female 225 45.2 10 116 48.6
Follow up time (years) Total 2 627 68 761
Median 5.0 (2.2-8.0) 2.1 (0.8-5.0)
VTE⁎ No 494 99.20 20 806 99.98
Yes 4 0.80 4 0.02
IQR, Interquartile range.
⁎ VTE, Venous thromboembolism.
341A.J. Walker et al. / Thrombosis Research 133 (2014) 340–344with cancer. Whilst routine prophylaxis is not advised for outpa-
tients recent updates to U.S. guidelines advise that prophylaxis is
recommended for patients with both cancer and additional risk
factors for thrombosis providing they are at low risk of bleeding
[13,14]. However it is not clear if children with malignancies might
beneﬁt from thromboprophylaxis [2].
The aim of the current study was to examine the risk of VTE in chil-
dren with cancer, using population-based English data.
Materials and Methods
We utilised population-based health registers to investigate the risk
of VTE in cancer patients under the age of 18 years from England (such
patients are hereby denoted “children”). Our cohort comprised children
who had linked data available from all three data sources described
below. A more detailed description of our methods, has been published
elsewhere [12].
Cancer Registry Data
Information on cancer diagnoses was obtained from the National
Cancer Intelligence Network (NCIN), which processes data supplied by
all regional cancer registries in the United Kingdom. Two related but
separate databasesmakeup the cancer registry data; theMergedCancer
Registry data (1990 to 2006, from English registries only) and the Ofﬁce
of National Statistics (ONS) minimum cancer dataset (1971 to 2006).
From these sources, we selected children with cancer diagnosed be-
tween April 1997 and December 2006 as this was the period from
which data linked to Clinical Practice Research Datalink (CPRD) and
Hospital Episodes Statistics (HES) were available. Cancers were classi-
ﬁed into 10 categories according to Cancer Research UK incidence
data. Cancers diagnosed outside these categories were referred to an
11th non-speciﬁed cancer category (“other site”).
Clinical Practice Research Datalink (CPRD)
Through the CPRD (formerly known as the General Practice Re-
search Database, GPRD), we were able to ascertain data on VTE. The
CPRD is an anonymised primary care database that was started in
1987 and now encompasses some 600 GP UK practices. This database
contains all recorded primary care data including clinical diagnoses,
treatments and outcomes. Data from the CPRD has been found to be
broadly representative of the UK population with regards to sex,
age, socio-economic status and geographic location [15], whilst the va-
lidity of coding has been demonstrated across a range of medical
conditions [16].
Hospital Episodes Statistics (HES)
The third database used in this paper is the Hospital Episodes Statis-
tics (HES) database. This is a secondary care database that enlists all
hospital admissions in England. For each inpatient episode we collected
data on all diagnoses and procedures. About half of the CPRD practices
are linked to the HES and cancer registry databases.
Exclusion Criteria
We excluded patients who (I) were from a CPRD practice that was
not linked to the HES and cancer registry databases; (II) had received
their cancer diagnosis outside the HES and CPRD registration dates;
(III)were diagnosedwith cancerwithin one year of registration at a par-
ticipating general practice; (IV) had a VTE diagnosis at any point prior to
the date of ﬁrst cancer diagnosis. Finally we excluded (V) all individuals
with a non-melanoma skin cancer.Comparison Cohort
The general population comparison cohort was identiﬁed from the
CPRD. In order tomaximize statistical power, all available controlswith-
out a diagnosis of cancer were eligible. Controls then received a pseudo-
diagnosis date generated at random within the registration period for
each patient. Any control whose pseudo-diagnosis date was after they
reached 18 years of age was then excluded.
VTE
Our outcome, VTE; was deﬁned according to relevant ICD codes
(I26.0, I26.9, I80, I80.1-I80.9, I81, I82, I82.0-I82.9) in HES and
Read codes mapped to these in the CPRD, if supported by any of the
following: (I) a prescription for an anticoagulant or evidence of
anticoagulation (based on Read codes) between 15 days before and
90 days after the VTE event, or (II) when the VTE was followed by
death within 30 days of the VTE diagnosis. We also accepted VTE
when listed as the underlying cause of death. Earlier data indicate that
VTE deﬁned according to primary care data has a high validity [17].
Statistics
Follow-up started at cancer diagnosis in cases or at pseudo-diagnosis
in controls respectively. It endedwith either a VTE event, death, emigra-
tion from a participating general practice or end of follow-up (Dec 31,
2010), whichever occurred earliest.
We calculated the rate of VTE according to number of VTEs per 1000
person-years of follow-up at risk. Through Cox regressionwe estimated
Hazard ratios for VTE in cancer patients compared to controls, adjusting
for sex, age at cancer diagnosis, and calendar year. All analyses were
carried out using STATA version 11.2 (Statacorp, 4905 Lakeway Drive,
College Station, Texas 77845, USA). P-values b0.05were considered sta-
tistically signiﬁcant.
Ethics
This study was approved by the CPRD Independent Scientiﬁc Advi-
sory Committee (Protocol no. 10–091).
Results
Four hundred and ninety eight (498) children with cancer fulﬁlled
our case criteria and were selected to the study group. The control
group comprised 20 810 children. The median age at ﬁrst cancer diag-
nosis was 7 years, with controls being 8 years at pseudo-diagnosis,
whilst 55% of cases (and 51% of controls) were male. Additional data
on participant characteristics, including total and median follow-up,
are given in Table 1. Of the 498 individuals with a diagnosis of cancer
during childhood, some 143 (28.7%) had leukemia, 80 (16.1%) tumours
of the brain and central nervous system, and 68 (13.7%) a lymphoma
(Table 2).
Table 2
Risk of venous thromboembolism in children with cancer.
No of children Rate per 1000 person-years;
95% CI
Controls (no cancer) 20 810 0.06; 0.02-0.15
All cancers 498 1.5; 0.6-4.1
Leukemias/Lymphomas 211 0.9; 0.1-6.1
Brain & CNS⁎ 80 0
Soft tissue sarcoma/Bone 54 8.1; 2.0-33.0
SNS tumours# 8 0
Renal 43 0
Carcinoma & malignant melanoma 18 0




Other site 52 4.0; 0.6-29.0
⁎ CNS, Central nervous system. # SNS, Sympathetic nervous system.
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During follow-up, four cancer patients and four controls were diag-
nosed with VTE. The cancer patients had diagnoses of hematological,
bone and non-speciﬁc cancers. The overall absolute VTE rate in children
with cancer was 1.52 per 1000 person-years (95%CI = 0.57-4.06) com-
paredwith 0.06 per 1000 person-years (95%CI = 0.02-0.15) in controls
(Table 2). Adjusting for sex and age at cancer diagnosis, this
corresponded to a HR of 28.3 for VTE (95%CI = 7.0-114.5). Further
data on VTE in children with cancer are given in Table 2.
Discussion
This study found a highly increased relative risk of VTE in children
with cancer compared to children without cancer. However absolute
risks of thromboembolism were very small and only about 1–2 per
1000 children with cancer per year had a VTE. Given these ﬁndings it is
not unreasonable for physicians to consider using thromboprophylaxis
in childrenwith cancer. However thismust be temperedwith the knowl-
edge that such a strategy would, almost inevitably, invoke adverse
events secondary to the drugs prescribed [18]. Notably we found that
the incidence of VTE in children in general is signiﬁcantly lower than in
adults and as routine thromboprophylaxis is generally not used for chil-
dren without other known risk factors before puberty in connection
with, for example, orthopedic surgery caution must be exercised prior
to acting on our ﬁndings in the clinical sphere.
Prior Literature
Several earlier studies have reported excess risks of thromboembo-
lism in pediatric cancer patients [6,7,19–31], but none of these studies
examined the relative risk of VTE in children with cancer compared to
that in a general population of children.
A single center study registry from Belarus reported that 2.1% (44/
2061) children with various malignancies had VTE [6] while a Canadian
study reported a higher prevalence of 7.6% (55/726) [7]. Children with
hematological malignancies are exposed to asparaginase and steroid in-
duced coagulation defects. Incidence of VTE in children with ALL varies
between 1 and 36% [32,33]. An American study reported a prevalence of
5% (27/501) for VTE in children with ALL [30], consistent with a meta-
analysis comprising 1752 childrenwith ALL and an overall risk of symp-
tomatic thrombosis of 5.2% [34]. In a randomized controlled trial where
study participants underwent three ultrasound investigations in six
months, some 36% of children with ALL had asyptomatic VTE [35]. Fur-
thermore, in another study 12% (9/75) of children with lymphoma de-
veloped thrombosis [36]. Less data is available on children with other
solid tumors; however, 14.3% (10/70) of children with sarcomasdeveloped thrombosis in a retrospective Canadian study [37]. In con-
trast, the incidence of VTE in children with brain tumors is relatively
low [38].
Strengths and Limitations
Themain strengths of this study are its population-based design, the
large number of childhood cancers and the general population compar-
ator. The cancers we studied are typical of those seen in children in the
UK, and we believe therefore that our results should be generalizable.
Based on almost 500 cancers in children, we had sufﬁcient statistical
power to detect an increase in risk of the magnitude we observed, but
were unable to explore the VTE risk in individual cancers. Also, based
on the upper conﬁdence limit for the absolute rate our study has sufﬁ-
cient power to suggest that the absolute VTE rate in children is unlikely
to be any higher than 0.4% per annum. Previous validation of the three
registers in this study show that they are suitable for research, where
the purpose is to calculate absolute and relative risks. However, these
registers do not contain detailed data on all relevant confounders, and
they do not contain data on mechanism of disease.
Unfortunatelywe also did not have any data on thromboprophylaxis
such as pharmacological anticoagulation or vena cavaﬁlters [2]. Howev-
er in the United Kingdom during the period of this study routine
thromboprophylaxis was not in use. We did not have access to data
on speciﬁc chemotherapeutic agents.
The use of ICD codes to identify VTE has recently been questioned
[39]. In this study we therefore requested additional proof of VTE for a
positive outcome and we believe that the risk of VTE misclassiﬁcation
is low. Yet, our stringent criteria may be part of the explanation for
the lower VTE rates (0.06/1000 person-years) we found than reported
elsewhere [40,41]. The higher rates in other studies may partly be due
to surveillance bias, where patients in smaller studies are intensively
monitored for VTE. Meanwhile, the VTE rate in our control population
was similar to that of the general population in other countries [42]. Ex-
tending the observation period to include the months immediately be-
fore diagnosis would not have substantially changed the observed rates,
as no VTE events occurred within this period.
Potential Mechanisms
Children with cancer have several risk factors for VTE including cen-
tral venous catheters (CVCs), chemotherapy, surgery infections and im-
mobility. There are probably other mechanisms, which may be cancer
speciﬁc and so explain why cancer site is important to the risk of VTE
in children [7]. The excess risk of VTE in ALL is largely thought to be
due L-asparaginase-induced antithrombin deﬁciency. In particular che-
motherapy with concomitant treatmentwith steroids and asparaginase
has been associated increased risk for thrombosis [21,34]. Most of the
VTEs in ALL occur during the induction or re-induction phases.
Clinical Implications
Given the increase in VTE in children with cancer we have observed
it might seem natural to use thromboprophylaxis in this high-risk pa-
tient group [2] but beneﬁts must be weighed against potential harm.
Currently there is no consensus nor evidence that anticoagulation in
children with cancer will prevent all VTE [35]. Cancer patients receiving
anticoagulant treatment following a VTE are at increased risk of bleed-
ing [43] (although some studies show only a small cumulative risk of
major bleeding [44]). The studies on VTE prophylaxis in children with
cancer are limited [35,45–48] and show contradictory results. To date
there are nodata uponwhich to base general recommendations for pro-
phylactic anticoagulation for children with malignancies.
Mitchell et al. [49]. suggested a predictive scoring system for identi-
fying children with leukemia at increased risk for thromboses. Their
method incorporates three leukemia protocols with different induction
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they identiﬁed 19 with high VTE risk. Of those, 8 received prophylactic
LMWH during induction and had a signiﬁcantly lower thrombosis rate
than those with high VTE risk without LMWH. However, as inherited
prothrombotic defects are rare and practically all children with cancer
have CVCs, the group with high VTE risk with this approach will be
limited.
Our study conﬁrms the high thrombosis risk in children with sarco-
mas observed previously in the Canadian study [37], although our esti-
mate has wide conﬁdence intervals.While brain tumours constitute the
second most frequent type of cancer in children [1], none of the 80 pa-
tients with brain or CNS tumours in our study had a VTE during
follow-up. The lack of VTE in children with brain tumours is consistent
with the lower risk of VTE in childrenwith brain tumours observed pre-
viously [7]. A recent review [2] found only four smaller studies on VTE
treatment in brain tumour patients with no deﬁnitive results and
hence it is beyond this study to suggest recommendations for
thromboprophylaxis in individual cancers.
Conclusion
In conclusion, children with cancer seem to be at a highly increased
risk of VTE, but absolute risks were small in the current study
with less than 1% of children having a VTE during an average follow-
up of 5 years. Considering earlier reports of an association between
thromboprophylaxis and bleeds, more information is needed before in-
stituting general thromboprophylaxis in children with cancer.
Role of the Funding Source
This study was funded by a project grant from Cancer Research UK
(Ref: C17683/A12079)
JW was funded by a Nottingham University/Nottingham University
Hospitals NHS Trust Senior Clinical Research Fellowship.
JFL was supported by grants from the Swedish Society of Medicine
and the Swedish Research Council (SIMSAM).
None of the funders had any inﬂuence on this study.
Author Contributions
Study concept and design: AJW, MJG, TRC, JW, SR, JFL
Acquisition of data: AJW and MJG
Analysis and interpretation of data: AJW, MJG, TRC, JW, SR, JFL
Wrote the ﬁrst draft of the manuscript: JFL
Critical revision of themanuscript for important intellectual content:
AJW, MJG, TRC, JW, SR, JFL
Statistical analysis: AJW
Study supervision: JFL and MJG
Conﬂict of Interest
No conﬂicts of interest to declare.
References
[1] Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, et al. Outcomes
for children and adolescents with cancer: challenges for the twenty-ﬁrst century.
J Clin Oncol 2010;28:2625–34.
[2] Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. Inter-
national clinical practice guidelines for the treatment and prophylaxis of venous
thromboembolism in patients with cancer. J Thromb Haemost 2013;11:56–70.
[3] Setty BA, O'Brien SH, Kerlin BA. Pediatric venous thromboembolism in the United
States: a tertiary care complication of chronic diseases. Pediatr Blood Cancer
2012;59:258–64.
[4] Prentiss AS. Early recognition of pediatric venous thromboembolism: a risk-
assessment tool. Am J Crit Care 2012;21:178–83 [quiz 84].
[5] Kelleher D, Shalhoub J, Davies AH. Venous thromboembolism in the paediatric pa-
tient. Phlebology 2012;27(Suppl. 2):81–5.[6] Lipay NV, Zmitrovich AI, Aleinikova OV. Epidemiology of venous thromboembolism
in children with malignant diseases: a single-center study of the Belarusian Center
for Pediatric Oncology and Hematology. Thromb Res 2011;128:130–4.
[7] Athale U, Siciliano S, Thabane L, Pai N, Cox S, Lathia A, et al. Epidemiology and clinical
risk factors predisposing to thromboembolism in childrenwith cancer. Pediatr Blood
Cancer 2008;51:792–7.
[8] Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is
a leading cause of death in cancer patients receiving outpatient chemotherapy. J
Thromb Haemost 2007;5:632–4.
[9] Boulet SL, Grosse SD, Thornburg CD, Yusuf H, Tsai J, Hooper WC. Trends in venous
thromboembolism-related hospitalizations, 1994–2009. Pediatrics 2012;130:e812–20.
[10] Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk fac-
tors, and trends for venous thromboembolism among hospitalized cancer patients.
Cancer 2007;110:2339–46.
[11] Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associatedwith
venous thromboembolism. N Engl J Med 2000;343:1846–50.
[12] Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboem-
bolism in patients with cancer – A cohort study using linked United Kingdom data-
bases. Eur J Cancer 2013;49(6):1404–13.
[13] Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in
nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th
ed: American College of Chest Physicians Evidence-Based Clinical Practice Guide-
lines. Chest 2012;141:e195S–226S.
[14] Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, et al. Venous
thromboembolic disease. J Natl Compr Canc Netw 2011;9:714–77.
[15] Lawrenson R,Williams T, Farmer R. Clinical information for research; the use of gen-
eral practice databases. J Public Health Med 1999;21:299–304.
[16] Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General
Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128–36.
[17] Lawrenson R, Todd JC, Leydon GM,Williams TJ, Farmer RD. Validation of the diagno-
sis of venous thromboembolism in general practice database studies. Br J Clin
Pharmacol 2000;49:591–6.
[18] Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Gottl U,
et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy
and Prevention of Thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e737S–801S.
[19] Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora
KW. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology
patients with central venous catheters. Eur J Pediatr 1999;158(Suppl. 3):S143–6.
[20] Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous
thrombin generation in children with acute lymphoblastic leukemia: risk of throm-
botic complications in L'Asparaginase-induced antithrombin III deﬁciency. Blood
1994;83:386–91.
[21] Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R.
Thrombotic events revisited in children with acute lymphoblastic leukemia: impact
of concomitant Escherichia coli asparaginase/prednisone administration. Thromb
Res 2001;103:165–72.
[22] Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M, et al. Pro-
spective study of hemostatic alterations in children with acute lymphoblastic leuke-
mia. Am J Hematol 2010;85:325–30.
[23] Elhasid R, Lanir N, Sharon R, Weyl Ben Arush M, Levin C, Postovsky S, et al. Prophy-
lactic therapy with enoxaparin during L-asparaginase treatment in children with
acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2001;12:367–70.
[24] Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D, Schobess R, Schumann
C, et al. Thromboembolic events in children with acute lymphoblastic
leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood
2003;101:2529–33.
[25] Nowak-Gottl U, Aschka I, Koch HG, Boos J, Dockhorn-Dworniczak B, Deufel T, et al.
Resistance to activated protein C (APCR) in children with acute lymphoblastic leu-
kaemia–the need for a prospective multicentre study. Blood Coagul Fibrinolysis
1995;6:761–4.
[26] Shapiro AD, Clarke SL, Christian JM, Odom LF, HathawayWE. Thrombosis in children
receiving L-asparaginase. Determining patients at risk. Am J Pediatr Hematol Oncol
1993;15:400–5.
[27] Pui CH, Chesney CM,Weed J, Jackson CW. Altered vonWillebrand factor molecule in
childrenwith thrombosis following asparaginase-prednisone-vincristine therapy for
leukemia. J Clin Oncol 1985;3:1266–72.
[28] Tuckuviene R, Christensen AL, Chan AK, Athale U. Bodymass index and thromboem-
bolism in children with hematological malignancies. Pediatr Blood Cancer 2012;59:
320–2.
[29] Al-Aridi C, Abboud MR, Saab R, Eid D, Jeha S, Chan AK, et al. Thrombosis in
children with acute lymphoblastic leukemia treated at a tertiary care center
in Lebanon: revisiting the role of predictive models. Pediatr Hematol Oncol
2011;28:676–81.
[30] Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, et al. The fre-
quency and management of asparaginase-related thrombosis in paediatric and
adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer
Institute consortium protocols. Br J Haematol 2011;152:452–9.
[31] Tousovska K, Zapletal O, Skotakova J, Bukac J, Sterba J. Treatment of deep venous
thrombosis with low molecular weight heparin in pediatric cancer patients: safety
and efﬁcacy. Blood Coagul Fibrinolysis 2009;20:583–9.
[32] Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol
2007;138:430–45.
[33] Nowak-Gottl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic
leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract
Res Clin Haematol 2009;22:103–14.
344 A.J. Walker et al. / Thrombosis Research 133 (2014) 340–344[34] Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al.
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-
analysis of 17 prospective studies comprising 1752 pediatric patients. Blood
2006;108:2216–22.
[35] Ruud E, HolmstromH, De Lange C, Hogstad EM,Wesenberg F. Low-dose warfarin for
the prevention of central line-associated thromboses in children with malignancies–
a randomized, controlled study. Acta Paediatr 2006;95:1053–9.
[36] Athale UH, Nagel K, Khan AA, Chan AK. Thromboembolism in childrenwith lympho-
ma. Thromb Res 2008;122:459–65.
[37] Athale U, Cox S, Siciliano S, Chan AK. Thromboembolism in children with sarcoma.
Pediatr Blood Cancer 2007;49:171–6.
[38] Bajzar L, Chan AK, Massicotte MP, Mitchell LG. Thrombosis in children with malig-
nancy. Curr Opin Pediatr 2006;18:1–9.
[39] Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjonneland A, Johnsen SP.
Venous thromboembolism discharge diagnoses in the Danish National Patient
Registry should be used with caution. J Clin Epidemiol 2010;63:223–8.
[40] AndrewM, David M, AdamsM, Ali K, Anderson R, Barnard D, et al. Venous thrombo-
embolic complications (VTE) in children: ﬁrst analyses of the Canadian Registry of
VTE. Blood 1994;83:1251–7.
[41] van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous
thromboembolism in childhood: a prospective two-year registry in The Netherlands.
J Pediatr 2001;139:676–81.
[42] Tuckuviene R, Christensen AL, Helgestad J, Johnsen SP, Kristensen SR. Pediatric ve-
nous and arterial noncerebral thromboembolism in Denmark: a nationwide
population-based study. J Pediatr 2011;159:663–9.[43] Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent
venous thromboembolism and bleeding complications during anticoagulant treat-
ment in patients with cancer and venous thrombosis. Blood 2002;100:3484–8.
[44] Bona RD, Hickey AD, Wallace DM. Warfarin is safe as secondary prophylaxis in pa-
tients with cancer and a previous episode of venous thrombosis. Am J Clin Oncol
2000;23:71–3.
[45] Massicotte P, Julian JA, GentM, Shields K, Marzinotto V, Szechtman B, et al. An open-
label randomized controlled trial of low molecular weight heparin for the preven-
tion of central venous line-related thrombotic complications in children: the
PROTEKT trial. Thromb Res 2003;109:101–8.
[46] Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison
of low-molecular-weight heparin and antithrombin versus antithrombin alone for
the prevention of symptomatic venous thromboembolism in children with acute
lymphoblastic leukemia. Pediatr Blood Cancer 2008;50:298–303.
[47] Mitchell L, AndrewM, Hanna K, Abshire T, Halton J, Wu J, et al. Trend to efﬁcacy and
safety using antithrombin concentrate in prevention of thrombosis in children re-
ceiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA
study. Thromb Haemost 2003;90:235–44.
[48] Halton JM, Mitchell LG, Vegh P, Eves M, Andrew ME. Fresh frozen plasma has no
beneﬁcial effect on the hemostatic system in children receiving L-asparaginase.
Am J Hematol 1994;47:157–61.
[49] Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, et al. Validation
of a predictive model for identifying an increased risk for thromboembolism in chil-
dren with acute lymphoblastic leukemia: results of a multicenter cohort study.
Blood 2010;115:4999–5004.
